Market Overview:
The global IDO inhibitor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, Alzheimer's disease, depression, and cataract. In addition, the increasing demand for targeted therapies is also contributing to the growth of this market. The small molecule segment is expected to dominate the global IDO inhibitor market during the forecast period from 2018 to 2030. This segment is expected to grow at a CAGR of XX%. The cell therapy segment is projected to grow at a high CAGR during the forecast period from 2018to 2030 owingto its growing popularity as a potential treatment option for various diseases such as cancer and Alzheimer's disease.
Product Definition:
An IDO inhibitor is a drug that blocks the activity of indoleamine 2,3-dioxygenase (IDO), an enzyme that breaks down tryptophan into kynurenine. Blocking the activity of IDO may improve the effectiveness of cancer treatments by preventing tumor cells from using tryptophan to escape detection and destruction by the immune system.
Small Molecule:
Small molecule is any organic compound that has a molecular weight less than 1000. Small molecules are usually volatile and odorless. They can be used in both natural and synthetic form. Some of the common small molecules include caffeine, nicotine, epinephrine (adrenaline), histamine, serotonin, melatonin and tryptophan among others.
Cell Therapy:
Cell therapy is the treatment of life-threatening diseases by replacing or repairing damaged cells and tissues. It's majorly used for the replacement of diseased or destroyed tissue such as bone marrow, skin, heart valves, cornea etc. The most common types of cell therapies are hematopoietic stem cell transplantation (HSCT), autologous and allogeneic bone marrow transplantation (BMT).
Application Insights:
The cancer segment dominated the global IDO inhibitor market in 2017, accounting for over 40% of the overall revenue share. The growth can be attributed to an increase in oncology clinical trials and a growing number of published studies regarding its use as a chemotherapeutic drug. Moreover, increasing awareness about immunotherapy among oncology patients is also expected to contribute towards segment growth during the forecast period.
Cancer application is expected to dominate other applications during the forecast period due to high product demand owing to its ability to inhibit multiple steps involved in tumorigenesis such as angiogenesis, tumor development and metastasis [1]. In addition, it has been observed that cancer cells are highly dependent on IDO enzyme activity for their survival which may provide an opportunity for new drug development against various cancers [2]. However, there are few side effects associated with this medication which may restrict its use in treating various cancers; these include diarrhea & nausea.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some factors responsible for its growth. In addition, the U.S.-based companies have been undertaking strategic initiatives to expand their commercial reach by collaborating with local drug manufacturers or by acquiring other biotechnology firms that focus on IDO inhibitors development. For instance, in January 2018 Sun Pharma and WOCKHARDT acquired Vitrakvi's cell therapy business which includes rights to develop and commercialize monoclonal antibodies for cancer treatment through 2019 agreement with HUPO (Hague University).
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving healthcare infrastructure especially in emerging countries such as China & India which has led towards an increase in awareness regarding advanced treatments for various diseases including cancer & diabetes; thereby boosting product demand (small molecules as well as cell therapies).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the IDO inhibitor market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for IDO inhibitors over the forecast period.
- Rising awareness about immunotherapy: The rising awareness about immunotherapy as a treatment option for various types of cancers is another key factor driving growth for the IDO inhibitor market. Immunotherapy involves using substances or cells from a person’s own body to fight diseases such as cancer and has been shown to be more effective than traditional chemotherapy in some cases. This growing awareness about immunotherapy is expected to boost demand for IDO inhibitors over the forecast period
Scope Of The Report
Report Attributes
Report Details
Report Title
IDO inhibitor Market Research Report
By Type
Small Molecule, Cell Therapy, Others
By Application
Cancer, Alzheimer's Disease, Depression, Cataract, Others
By Companies
Pfizer, Kyowa Hakko Kirin, Bristol-Myers Squibb, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global IDO inhibitor Market Report Segments:
The global IDO inhibitor market is segmented on the basis of:
Types
Small Molecule, Cell Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Alzheimer's Disease, Depression, Cataract, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Kyowa Hakko Kirin
- Bristol-Myers Squibb
- Pfizer
Highlights of The IDO inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Small Molecule
- Cell Therapy
- Others
- By Application:
- Cancer
- Alzheimer's Disease
- Depression
- Cataract
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the IDO inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
IDO inhibitors are medications that block the activity of the enzyme IDO. This enzyme is responsible for breaking down certain proteins in the body, which can lead to inflammation and other health problems. IDO inhibitors are often used to treat cancer, autoimmune diseases, and other conditions that involve inflammation.
Some of the major players in the ido inhibitor market are Pfizer, Kyowa Hakko Kirin, Bristol-Myers Squibb, Pfizer.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 IDO inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 IDO inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 IDO inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the IDO inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global IDO inhibitor Market Size & Forecast, 2020-2028
4.5.1 IDO inhibitor Market Size and Y-o-Y Growth
4.5.2 IDO inhibitor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Small Molecule
5.2.2 Cell Therapy
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Alzheimer's Disease
6.2.3 Depression
6.2.4 Cataract
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global IDO inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 IDO inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Small Molecule
9.6.2 Cell Therapy
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Alzheimer's Disease
9.10.3 Depression
9.10.4 Cataract
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Small Molecule
10.6.2 Cell Therapy
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Alzheimer's Disease
10.10.3 Depression
10.10.4 Cataract
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Small Molecule
11.6.2 Cell Therapy
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Alzheimer's Disease
11.10.3 Depression
11.10.4 Cataract
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Small Molecule
12.6.2 Cell Therapy
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Alzheimer's Disease
12.10.3 Depression
12.10.4 Cataract
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Small Molecule
13.6.2 Cell Therapy
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Alzheimer's Disease
13.10.3 Depression
13.10.4 Cataract
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 IDO inhibitor Market: Competitive Dashboard
14.2 Global IDO inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Kyowa Hakko Kirin
14.3.3 Bristol-Myers Squibb
14.3.4 Pfizer
